%0 Journal Article
%A Trewin-Nybråten, Cassia B
%A Leithe, Sigrid
%A Paulsen, Torbjørn
%A Langseth, Hilde
%A Fortner, Renée Turzanski
%T Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway.
%J British journal of cancer
%V 132
%N 12
%@ 0007-0920
%C Edinburgh
%I Nature Publ. Group
%M DKFZ-2025-00874
%P 1158-1166
%D 2025
%Z #LA:C020# / 2025 Jun;132(12):1158-1166
%X Residual disease (RD) following cytoreductive surgery is prognostic for epithelial ovarian cancer (EOC) patients. Few studies have evaluated RD and survival by tumor histotype and across continuous RD diameter.2608 individuals with stages III-IV invasive EOC diagnosed between 2013 and 2022 were identified using the Cancer Registry of Norway. In flexible parametric models, we compared excess mortality comparing RD versus no macroscopic residual disease (NMRD); systemic anti-cancer therapy was evaluated in a sub-cohort from 2019. Excess mortality was assessed across continuous RD size using restricted cubic splines.Among 1849 patients with cytoreductive surgery, survival was worse for individuals with RD (vs. NMRD), excess hazard ratio (EHR) = 2.62 (95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40287590
%R 10.1038/s41416-025-03018-0
%U https://inrepo02.dkfz.de/record/300694